Target
Galectin-3
Ligand
BDBM468289
Substrate
n/a
Meas. Tech.
Evaluation of Kd Values
Kd
72.0±n/a nM
Citation
 Leffler, HNilsson, UZetterberg, F Hybrid galactoside inhibitor of galectins US Patent  US10800804 Publication Date 10/13/2020 
Target
Name:
Galectin-3
Synonyms:
LEG3_HUMAN | LGALS3 | MAC2
Type:
Enzyme
Mol. Mass.:
26156.54
Organism:
Homo sapiens (Human)
Description:
P17931
Residue:
250
Sequence:
MADNFSLHDALSGSGNPNPQGWPGAWGNQPAGAGGYPGASYPGAYPGQAPPGAYPGQAPPGAYPGAPGAYPGAPAPGVYPGPPSGPGAYPSSGQPSATGAYPATGPYGAPAGPLIVPYNLPLPGGVVPRMLITILGTVKPNANRIALDFQRGNDVAFHFNPRFNENNRRVIVCNTKLDNNWGREERQSVFPFESGKPFKIQVLVEPDHFKVAVNDAHLLQYNHRVKKLNEISKLGISGDIDLTSASYTMI
  
Inhibitor
Name:
BDBM468289
Synonyms:
3′-{4-[(Butylamino)carbonyl]-1H-1,2,3-triazol-1-yl}-3′deoxy-3-O-[(5,6-difluoro-2-oxo-3-chromenyl)methyl]-1,1′-sulfanediyl-di-β-D-galactopyranoside | US10800804, Example S8c
Type:
Small organic molecule
Emp. Form.:
C29H36F2N4O12S
Mol. Mass.:
702.678
SMILES:
CCCCNC(=O)c1cn(nn1)[C@H]1[C@@H](O)C(CO)O[C@@H](SC2O[C@H](CO)C(O)C(OCc3cc4c(F)c(F)ccc4oc3=O)[C@H]2O)C1O |r|
Structure:
Search PDB for entries with ligand similarity: